Pricing Log in Create free account
Friday 6 November 2026 Export RVMD’s income statement to Excel — free account

Revolution Medicines, Inc.

RVMD Healthcare Biotechnology

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.

Revenue
+1,188.7%
EPS
−18.0%
Free cash flow
−99.1%
Total debt
+322.7%

Quarter to September 2026, against a year earlier

193.05 15.40 +8.67%
Market cap
$38.1B
P/E
0.0×
Fwd P/E
−11.9×
Dividend yield
—
F-score
4/9
Altman Z
7.73
Beneish M
−4.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Revolution Medicines, Inc. 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:10 PM ET · Document on sec.gov · Filing index

Red flags

  • Short cash runway

    Revolution Medicines, Inc.’s cash and short-term investments cover about 1.6 quarters of its operating cash burn

    10-Q filed · The filing · sec.gov

  • Share dilution

    Shares outstanding rose 11.9% in a year, to 216.3 million

    10-Q filed · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2026: 19 added · 7 removed · 51 modified; 10 with only figures updated

  1. Modified · Overview

    We are a late-stage clinicalglobal, commercial-stage oncology company dedicated to discovering, developing and commercializing novel targeted therapies for patients with RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens. Our research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors) that are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.